Every 10-Q that GLOBUS MEDICAL INC (GMED) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GMED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GMED filings page.
Globus Medical, Inc. reported higher net sales of $789,612 (in thousands) for the quarter ended June 30, 2026 and $1,549,466 (in thousands) for the first half of 2026. Operating income was $182,432 and $332,820 (in thousands), supported by lower cost of sales, acquisition-related and restructuring expenses.
Net income was $151,569 for the quarter and $275,871 (in thousands) year-to-date, with diluted EPS of $1.10 and $2.00, respectively. Prior-year results included a bargain purchase gain of $110,561 (in thousands) from the Nevro acquisition versus $1,118 (in thousands) recognized in 2026.
Cash and cash equivalents totaled $507,745 (in thousands), alongside short-term marketable securities of $87,397 (in thousands) and long-term marketable securities of $245,358 (in thousands). Operating activities generated $412,105 (in thousands) of cash in the first half. The company repurchased 1.6 million Class A shares for $136.1 million under its $500.0 million authorization and had no outstanding borrowings under its $400.0 million revolving credit facility or 0.375% senior convertible notes. Litigation reserves included a previously recorded $43.1 million provision for the Pimenta matter, while other significant cases continue without additional accruals beyond legal fees.
Globus Medical, Inc. reported sharply higher quarterly results for the three months ended March 31, 2026. Net sales rose to $759.9 million from $598.1 million a year earlier, while net income increased to $124.3 million from $75.5 million. Diluted earnings per share improved to $0.90 from $0.54.
Growth came from both U.S. and international markets and reflects the integration of the 2025 Nevro acquisition, which contributed $82.7 million in revenue. The company generated $202.4 million in cash from operating activities, maintained a strong cash and investments position, and recorded ongoing restructuring and acquisition-related costs while continuing to invest in R&D and enabling technologies.
Globus Medical (GMED) reported strong Q3 2025 results. Net sales were $769.0 million versus $625.7 million a year ago, and operating income rose to $137.4 million from $48.1 million. Net income was $119.0 million with diluted EPS of $0.88, up from $0.38. For the first nine months, net sales reached $2.11 billion and net income was $397.3 million, which includes a bargain purchase gain tied to the Nevro transaction.
The company completed the Nevro acquisition on April 3, 2025 for total purchase price of $252.5 million and recorded a bargain purchase gain of $114.4 million year‑to‑date. Musculoskeletal Solutions drove Q3 with $741.0 million in sales, while Enabling Technologies contributed $28.0 million.
Globus ended the quarter with cash and cash equivalents of $371.8 million. Year‑to‑date operating cash flow was $504.9 million. Financing uses included repayment of senior convertible notes of $450.0 million and common stock repurchases of $255.5 million. Inventories were $771.5 million. Shares outstanding were 133,839,166 as of November 3, 2025; this is a baseline figure, not the amount being offered.